Table 2 Treatment duration per TKI and median time to switch
From: A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia
Imatinib n = 31 | Nilotinib n = 43 | Dasatinib n = 27 | Ponatinib n = 5 | Bosutinib n = 6 | Generic imatinib n = 1 | |
|---|---|---|---|---|---|---|
Median treatment duration, months (IQR) | 14.3 (3.0–43.2) | 24.0 (7.5–43.9) | 22.4 (6.4–36.7) | 8.4 (7.6–16.8) | 4.8 (0.2–11.7) | 20.3 (20.3–20.3) |
N x months | 812 | 1216 | 610 | 73.5 | 66 | 20.3 |
Total patient years | 67 | 101 | 50.8 | 6.1 | 5.5 | 1.7 |
Median time to switch (estimate), months (95% CI) | 25.4 (0.0–53.5) | 69.3 (44.2–94.4) | 22.2 (0.0–45.5) | 4.0 | N.A. | 19.8 |